Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis

Abstract

Chronic hepatitis C with cirrhosis is treated with direct-acting antibiotics (DAAs). The aim of this study was to investigate the effect of direct-acting antibodies in the treatment of hepatitis C in cirrhosis. It also examines the proportion of drug-related problems, side effects, and mortality. The Cochrane Library and PubMed were thoroughly searched for the required literature. Fifteen articles were extracted for inclusion in this systematic review and meta-analysis. A total of 16 studies were thoroughly screened. The included studies provided a comprehensive picture of the effects of DAA therapy, spanning multiple study designs and sites Our analysis showed that good responses were observed with DAA regimens and that treatment discontinuation was low due to adverse events a stirring that. Few adverse events were reported, but all were mostly uncontrolled to prevent treatment discontinuation or death. In addition, meta-analytic studies on specific outcomes such as encephalopathy, ascites, hepatocellular carcinoma (HCC), adverse events, and death provided quantitative analysis about the safety of DAAs. Research also shows that DAAs have fewer side effects, deaths, and complications than other treatments.